Table 1 Clinical characteristics of the study population.
Discovery set (iTRAQ 5-Plex) (set 1) (n = 50) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
Control (n = 10) | TOFa (n = 10) | VSDb (n = 10) | PTAc (n = 10) | MIXd (n = 10) | |||||
MAe (y) | 28.0 ± 2.7 | 29.0 ± 2.9 | 29.2 ± 1.6 | 27.8 ± 5.3 | 29.9 ± 2.9 | ||||
GAf (w) | 24.0 ± 0.7 | 23.8 ± 0.8 | 24.4 ± 0.9 | 24.8 ± 2.2 | 24.2 ± 1.0 | ||||
MRM-Validation set (set 2) (n = 42) | |||||||||
Control (n = 20) | CHD (n = 22) | ||||||||
TOF (n = 4) | VSD (n = 4) | PTA (n = 4) | TOAg (n = 4) | HLHSh (n = 3) | SVi (n = 3) | ||||
MA | 27.1 ± 5.0 | 30.6 ± 2.6 | 28.4 ± 1.7 | 29.0 ± 2.9 | 28.0 ± 1.1 | 28.7 ± 5.1 | 27.7 ± 4.7 | ||
GA | 24.2 ± 1.4 | 24.2 ± 1.6 | 23.4 ± 1.1 | 24.0 ± 1.4 | 24.4 ± 1.7 | 24.7 ± 2.3 | 23.3 ± 1.5 | ||
ELISA-Validation set (set 3) (n = 178) | |||||||||
Control (n = 60)▲ | CHD (n = 118) | ||||||||
TOF (n = 41) | VSD (n = 21) | TOA (n = 13) | PTA (n = 12) | HLHS (n = 10) | SV (n = 6) | PSj (n = 6) | OTk (n = 9) | ||
MA | 28.4 ± 4.2 | 29.8 ± 4.8 | 27.3 ± 4.0 | 27.1 ± 3.7 | 28.0 ± 3.9 | 26.4 ± 5.4 | 29.0 ± 3.8 | 28.8 ± 3.8 | 28.3 ± 3.9 |
GA | 24.3 ± 1.4 | 24.5 ± 1.5 | 23.6 ± 1.4 | 24.6 ± 1.1 | 24.3 ± 1.5 | 24.5 ± 1.3 | 23.7 ± 1.0 | 24.7 ± 1.2 | 23.9 ± 1.3 |
Different GA set (normal pregnancy) (set 4) (n = 160) | |||||||||
8–10w (n = 20) | 16–19w (n = 20) | 22–26w (n = 60)▲ | 32–34w (n = 20) | 38–40w (n = 20) | NPl (n = 20) | ||||
MA | 29.4 ± 4.9 | 28.9 ± 3.2 | 28.4 ± 4.2 | 29.1 ± 4.4 | 29.3 ± 3.9 | 29.5 ± 3.0 | |||
GA | 9.1 ± 0.8 | 17.6 ± 1.1 | 24.3 ± 1.4 | 32.8 ± 0.8 | 38.6 ± 0.7 | 0 | |||
Heart tissue specimens (set 5) (n = 8) | |||||||||
CHD cohort | Control cohort | ||||||||
Defects | TOA | PTA | TOF | TOF | Control 1 | Control 2 | Control 3 | Control 4 | |
MA | 28 | 30 | 26 | 25 | 24 | 26 | 27 | 30 | |
GA | 23 | 25 | 25 | 26 | 22 | 24 | 25 | 26 | |
Gender | female | male | male | female | female | male | male | female | |
